Literature DB >> 15277640

Prion protein codon 129 polymorphism and risk of Alzheimer disease.

M Riemenschneider1, N Klopp, W Xiang, S Wagenpfeil, C Vollmert, U Müller, H Förstl, T Illig, H Kretzschmar, A Kurz.   

Abstract

The authors investigated the PRNP Met129Val polymorphism in 1,393 subjects including 482 patients with Alzheimer disease (AD) and two independent control groups. In patients, PRNP Met homozygosity conferred increasing risk with decreasing age at onset (onset: 61 to 70 years, n = 151, p = 0.02, odds ratio [OR] = 1.72, 95% CI = 1.2 to 2.53; onset: < or =60 years, n = 138, p = 0.013, OR = 1.92, 95% CI = 1.31 to 2.87), whereas no association was obtained in patients with onset at older than 70 years. The results suggest involvement of the prion protein in the pathogenesis of early-onset AD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15277640     DOI: 10.1212/01.wnl.0000130198.72589.69

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  36 in total

1.  Prion protein gene M129 allele is a risk factor for Alzheimer's disease.

Authors:  M Gacia; K Safranow; M Styczyńska; K Jakubowska; B Pepłońska; M Chodakowska-Zebrowska; I Przekop; A Słowik; E Golańska; K Hułas-Bigoszewska; D Chlubek; D Religa; C Zekanowski; M Barcikowska
Journal:  J Neural Transm (Vienna)       Date:  2006-08-08       Impact factor: 3.575

2.  Interaction between prion protein and interleukin-1A genes increases early-onset Alzheimer's disease risk.

Authors:  Onofre Combarros; Javier Llorca; Pascual Sánchez-Juan; Ignacio Mateo; Jon Infante; Eloy Rodríguez; Coro Sánchez-Quintana; José Berciano
Journal:  J Neurol       Date:  2007-02-14       Impact factor: 4.849

Review 3.  Beta-secretase: structure, function, and evolution.

Authors:  Chitra Venugopal; Christina M Demos; K S Jagannatha Rao; Miguel A Pappolla; Kumar Sambamurti
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-06       Impact factor: 4.388

4.  Alzheimer's amyloid-β oligomers rescue cellular prion protein induced tau reduction via the Fyn pathway.

Authors:  Rong-Jie Chen; Wei-Wei Chang; Yu-Chun Lin; Pei-Lin Cheng; Yun-Ru Chen
Journal:  ACS Chem Neurosci       Date:  2013-07-18       Impact factor: 4.418

5.  Prion-like disorders: blurring the divide between transmissibility and infectivity.

Authors:  Mimi Cushman; Brian S Johnson; Oliver D King; Aaron D Gitler; James Shorter
Journal:  J Cell Sci       Date:  2010-04-15       Impact factor: 5.285

Review 6.  Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders.

Authors:  Vijay K Ramanan; Andrew J Saykin
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

Review 7.  Beta-amyloid oligomers and cellular prion protein in Alzheimer's disease.

Authors:  Erik C Gunther; Stephen M Strittmatter
Journal:  J Mol Med (Berl)       Date:  2009-12-04       Impact factor: 4.599

8.  Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers.

Authors:  Juha Laurén; David A Gimbel; Haakon B Nygaard; John W Gilbert; Stephen M Strittmatter
Journal:  Nature       Date:  2009-02-26       Impact factor: 49.962

Review 9.  Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders.

Authors:  Yahya E Choonara; Viness Pillay; Lisa C Du Toit; Girish Modi; Dinesh Naidoo; Valence M K Ndesendo; Sibongile R Sibambo
Journal:  Int J Mol Sci       Date:  2009-06-03       Impact factor: 6.208

10.  Lack of TAR-DNA binding protein-43 (TDP-43) pathology in human prion diseases.

Authors:  A M Isaacs; C Powell; T E Webb; J M Linehan; J Collinge; S Brandner
Journal:  Neuropathol Appl Neurobiol       Date:  2008-08       Impact factor: 8.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.